CNBCのインスタグラム(cnbc) - 8月5日 06時01分

The NIH said it is starting two trials testing whether an experimental antibody drug can work as a safe and effective treatment in patients with Covid-19.⁠
⁠
The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly’s experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech AbCellera. The companies announced Monday they began a phase three trial testing whether the treatment can prevent the spread of coronavirus in residents and staff at nursing homes.⁠
⁠
One of the trials will test Eli Lilly’s experimental treatment on people with mild to moderate Covid-19 symptoms who have not been hospitalized. The second trial, in a late stage, will look patients who have been hospitalized with mild to moderate Covid-19 with fewer than 13 days of symptoms and aims to enroll a total of 1,000 people.⁠
⁠
When should we expect results from the trial? Details at the link in bio.⁠

[BIHAKUEN]UVシールド(UVShield)

>> 飲む日焼け止め！「UVシールド」を購入する